CL2019003254A1 - Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas. - Google Patents

Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.

Info

Publication number
CL2019003254A1
CL2019003254A1 CL2019003254A CL2019003254A CL2019003254A1 CL 2019003254 A1 CL2019003254 A1 CL 2019003254A1 CL 2019003254 A CL2019003254 A CL 2019003254A CL 2019003254 A CL2019003254 A CL 2019003254A CL 2019003254 A1 CL2019003254 A1 CL 2019003254A1
Authority
CL
Chile
Prior art keywords
ester
vitamin
formulation based
treat bacterial
fungal
Prior art date
Application number
CL2019003254A
Other languages
English (en)
Inventor
Giorgio Panin
Original Assignee
Biologa Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biologa Srl filed Critical Biologa Srl
Publication of CL2019003254A1 publication Critical patent/CL2019003254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA FORMULACIÓN PARA USO TÓPICO BASADA EN VITAMINA E O UN ÉSTER DE LA MISMA PARA USARSE EN LA REMOCIÓN, REDUCCIÓN O INHIBICIÓN DE UNA BIOPELÍCULA BACTERIANA Y/O FÚNGICA, DONDE EL ÉSTER DE VITAMINA E ES UN ÉSTER CON UN ÁCIDO CARBOXÍLICO DE FÓRMULA R-COOH, EN LA CUAL R ES UN RADICAL ALQUILO QUE TIENE DE 1 A 19 ÁTOMOS DE CARBONO O UN ALQUENILO O ALQUINILO QUE TIENE DE 2 A 19 ÁTOMOS DE CARBONO.
CL2019003254A 2017-05-29 2019-11-13 Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas. CL2019003254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Publications (1)

Publication Number Publication Date
CL2019003254A1 true CL2019003254A1 (es) 2020-07-03

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003254A CL2019003254A1 (es) 2017-05-29 2019-11-13 Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.

Country Status (22)

Country Link
US (3) US20200360339A1 (es)
EP (1) EP3630092B1 (es)
CN (1) CN110650737A (es)
AU (1) AU2018275487B2 (es)
BR (1) BR112019023962A8 (es)
CA (1) CA3061568C (es)
CL (1) CL2019003254A1 (es)
DK (1) DK3630092T3 (es)
EA (1) EA201992190A1 (es)
ES (1) ES2919423T3 (es)
GE (1) GEP20207179B (es)
HR (1) HRP20220808T1 (es)
HU (1) HUE059185T2 (es)
IT (1) IT201700058311A1 (es)
LT (1) LT3630092T (es)
MA (1) MA48936B1 (es)
MX (1) MX2019013559A (es)
PL (1) PL3630092T3 (es)
PT (1) PT3630092T (es)
RS (1) RS63347B1 (es)
SI (1) SI3630092T1 (es)
WO (1) WO2018219862A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT1302275B1 (it) * 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
EP2418945B1 (en) * 2009-04-15 2018-12-05 BMG PHARMA S.p.A. Mineral salt-sulfonic acid compositions and methods of use
ITUB20153889A1 (it) * 2015-09-25 2017-03-25 Bio Lo Ga Srl Gel idrofobico a base di vitamina E esente da prodotti siliconici per applicazione topica
ITUB20169882A1 (it) * 2016-01-08 2017-07-08 Flame S R L Vitamina E per l’uso nel trattamento e nella prevenzione delle infezioni da biofilm.
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Also Published As

Publication number Publication date
RS63347B1 (sr) 2022-07-29
WO2018219862A1 (en) 2018-12-06
MA48936B1 (fr) 2022-08-31
SI3630092T1 (sl) 2022-08-31
US20200121638A1 (en) 2020-04-23
MX2019013559A (es) 2022-02-03
GEAP201815201A (es) 2020-07-27
BR112019023962A2 (pt) 2020-06-09
HUE059185T2 (hu) 2022-10-28
PT3630092T (pt) 2022-06-02
US20210228541A1 (en) 2021-07-29
LT3630092T (lt) 2022-06-27
PL3630092T3 (pl) 2022-09-12
CA3061568A1 (en) 2018-12-06
ES2919423T3 (es) 2022-07-26
EP3630092B1 (en) 2022-04-13
EP3630092A1 (en) 2020-04-08
IT201700058311A1 (it) 2018-11-29
EA201992190A1 (ru) 2020-09-03
CA3061568C (en) 2024-02-13
HRP20220808T1 (hr) 2022-09-30
MA48936A (fr) 2020-04-08
AU2018275487B2 (en) 2024-03-14
US11234958B2 (en) 2022-02-01
BR112019023962A8 (pt) 2022-07-05
US20200360339A1 (en) 2020-11-19
CN110650737A (zh) 2020-01-03
AU2018275487A1 (en) 2019-11-07
DK3630092T3 (da) 2022-06-20
GEP20207179B (en) 2020-11-10

Similar Documents

Publication Publication Date Title
CO2020014009A2 (es) Inhibidores de mcl-1
BR112018073329A2 (pt) combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase
BR112018015294A2 (pt) método e sistema para filetar um substrato metálico em uma unidade de laminação.
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
CL2016001636A1 (es) Mezclas fungicidas sinérgicas para el control fúngico en cereales
PE20190207A1 (es) Composiciones que comprenden cepas bacterianas
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
RS54261B1 (en) USE OF SGC STIMULATORS, SGC ACTIVATORS, INDIVIDUALLY AND IN COMBINATION WITH PDE5 INHIBITORS FOR SYSTEMIC SCLEROSIS TREATMENT (SSC)
CL2019003402A1 (es) Composiciones sólidas para administración oral.
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
BR112016006048A8 (pt) composições antimicrobianas
CL2017000014A1 (es) Derivados de isondolina para su uso en el tratamiento de una infección viral
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
AR098888A1 (es) Composición para el cuidado oral
UY36116A (es) Aplicaciones volátiles contra patógenos
AR101581A1 (es) Composición de colutorio
AR102790A1 (es) Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies
CL2018001221A1 (es) Modular la expresión de apolipoproteína (a)
CL2021001246A1 (es) Moduladores de expresión irf5.
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CY1122289T1 (el) Φαρμακευτικη συνθεση για χρηση στην αυξηση του τροφισμου της ρινικης βλεννογονου
CL2019003254A1 (es) Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.
PE20220129A1 (es) Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.